News Sentiment

PRME sentiment intelligence

Prime Medicine, Inc. Common Stock news scored across direct company coverage, industry context, sector read-through, source quality, and freshness.

Chart Weekly report Factors RSS feed
Weighted score 58 Balanced news tone 75 relevant articles
Exchange NASDAQ United States
Sector Healthcare Market context
Industry Biotechnology Read-through group
Latest close 3.78 Week of 10 Jul 2026
Weighted tone 58/100

Balanced news tone

Market reaction Balanced read

News tone and price action are not far from neutral.

Primary event Market update

79/100 classification confidence.

Company focus 68

directly relevant articles

Source quality 4

high-authority source matches

Trend context Trend inactive

-2.3% over one week, +36.2% over four weeks, trend inactive, and below fair value.

Latest direct headline Positive

Prime Medicine (PRME) Reaches Positive Resolution to Arbitration with Beam Therapeutics

Market Reaction

Balanced read

67/100 confidence

News tone and price action are not far from neutral.

Primary event Market update 79/100 classification
One-week reaction -2.3% Price reacting lower
Trend fit Trend inactive 36.2% over four weeks
Fair value -24.4% Below fair value
Value support

Sentiment Mix

Positive, neutral, negative

Weighted by relevance
Positive 26
Neutral 42
Negative 7

Relevance

Why the article matched

Direct first
Direct company coverage 68
Industry context 7
Sector context 0

Sources

Coverage mix

Publishers
Market source 7
Investing.com 6
TradingView 5
Moomoo 5
Stock Titan 4
MarketBeat 3
Insider Monkey 2
timothysykes.com 2

Event Lens

What the news is about

Classified themes
Market update 39
Earnings 21
Analyst action 6
Regulatory and legal 6
Balance sheet 2
Guidance 1

Sentiment Trail

Score over time

50 baseline
Above 50 Neutral zone Below 50

News Tape

Relevant headlines

Showing 1-30 of 75
MarketBeat Direct company coverage

Sumitomo Mitsui Trust Group Inc. Has $10.23 Million Stock Position in Prime Medicine, Inc. $PRME

Sumitomo Mitsui Trust Group Inc. reduced its stake in Prime Medicine (NASDAQ:PRME) by 9.4% in the first quarter, now holding 2.94 million shares valued at $10.23 million. Despite this reduction, institutional ownership remains high at 70.37%, with other major institutional invest

Tone
Neutral 50/100
Event
Earnings
Published
15 Jul 2026 08:51
Source
MarketBeat
timothysykes.com Direct company coverage

Prime Medicine Stock Dips As Traders Weigh Heavy Losses

Prime Medicine Inc. (PRME) stock has dipped by 9.69% due to negative sentiment surrounding its latest pipeline developments and significant financial losses despite minimal revenue. The company is characterized as a high-risk, early-stage gene-editing platform with a limited cash

Tone
Negative 8/100
Event
Earnings
Published
11 Jul 2026 15:11
Source
timothysykes.com
TradingView Direct company coverage

Enterprise value to EBITDA forward of Prime Medicine, Inc. – NASDAQ:PRME

This article provides financial information for Prime Medicine, Inc. (NASDAQ: PRME), specifically its enterprise value to EBITDA forward. It notes that the market is currently closed with no trades. The article is primarily a data point page from TradingView, focusing on key fina

Tone
Neutral 50/100
Event
Market update
Published
11 Jul 2026 10:10
Source
TradingView
MSN Direct company coverage

Prime Medicine gains after winning arbitration with Beam Therapeutics

Prime Medicine's stock rose in after-hours trading following a favorable decision in its arbitration with Beam Therapeutics. The arbitration ruling confirmed that Prime Medicine holds exclusive rights to certain foundational intellectual property for its PRIME editing technology.

Tone
Positive 86/100
Event
Market update
Published
11 Jul 2026 08:10
Source
MSN
StocksToTrade Direct company coverage

PRME Stock Slides As Traders Weigh Heavy Losses And Cash Runway

Prime Medicine Inc. (PRME) stock is down over 10% as traders react to its heavy losses and uncertain cash runway despite an earlier rally. While the company boasts high gross margins and some liquidity with $135.5M in cash, it faces significant quarterly net losses and R&D spendi

Tone
Negative 29/100
Event
Balance sheet
Published
10 Jul 2026 17:41
Source
StocksToTrade
AllSci Direct company coverage

Prime Medicine Wins AATD Gene Therapy Arbitration

Prime Medicine has won an arbitration against Beam Therapeutics, confirming its exclusive development rights for PM647, a prime editing therapy for alpha-1 antitrypsin deficiency (AATD). This decision clears PM647 for clinical entry, with an IND/CTA filing targeted for Q3 2026 an

Tone
Positive 71/100
Event
Market update
Published
09 Jul 2026 12:39
Source
AllSci
Moomoo Direct company coverage

Prime Medicine Shares Rise on Positive Arbitration Ruling in Beam Dispute

Prime Medicine's shares saw a significant increase following an arbitration panel's ruling in its favor against Beam Therapeutics, upholding the validity of certain intellectual property licensed exclusively to Prime Medicine. The decision confirms the validity of foundational pa

Tone
Positive 71/100
Event
Market update
Published
09 Jul 2026 08:11
Source
Moomoo
MarketBeat Direct company coverage

Prime Medicine, Inc. (NASDAQ:PRME) Given Consensus Recommendation of "Moderate Buy" by Analysts

Analysts have given Prime Medicine, Inc. (NASDAQ:PRME) a consensus "Moderate Buy" rating, with an average 12-month price target of $7.53. The stock rose 15.8% recently, trading at $4.62, below its 52-week high of $6.94. The company reported a wider-than-expected quarterly loss of

Tone
Neutral 50/100
Event
Analyst action
Published
09 Jul 2026 08:11
Source
MarketBeat
The Boston Globe Direct company coverage

Prime Medicine claims victory in dispute over gene-editing technology with Beam Therapeutics

Prime Medicine has won an arbitration dispute against Beam Therapeutics regarding gene-editing technology for alpha-1 antitrypsin deficiency (AATD). The ruling allows Prime to proceed with clinical trials for AATD and is a setback for Beam, which called the decision disagreed wit

Tone
Positive 73/100
Event
Market update
Published
08 Jul 2026 21:09
Source
The Boston Globe
Investing.com Direct company coverage

Prime Medicine stock surges after winning arbitration with Beam

Prime Medicine Inc. (NASDAQ: PRME) shares rose significantly after the company won a binding arbitration ruling against Beam Therapeutics Inc. (NASDAQ: BEAM). The ruling confirms Prime Medicine's development rights to PM647, an investigational treatment for Alpha-1 Antitrypsin De

Tone
Positive 87/100
Event
Regulatory and legal
Published
08 Jul 2026 14:41
Source
Investing.com
Fierce Biotech Direct company coverage

Prime wins patent fight with Beam to continue work on AATD gene editing therapy

Prime Medicine has won a patent dispute against Beam Therapeutics, allowing it to continue developing its lead gene-editing therapy, PM647, for alpha-1 antitrypsin deficiency (AATD). The arbitration tribunal ruled that Prime did not violate its 2019 agreement with Beam and does n

Tone
Positive 72/100
Event
Market update
Published
08 Jul 2026 14:40
Source
Fierce Biotech
TipRanks Direct company coverage

Prime Medicine resolves arbitration, clarifying PM647 development rights

Prime Medicine, Inc. announced that an arbitration tribunal ruled in its favor regarding its PM647 development candidate, affirming it falls within Prime's agreed field and dismissing Beam Therapeutics' claims. This resolution clarifies Prime Medicine's development rights and rem

Tone
Positive 65/100
Event
Market update
Published
08 Jul 2026 12:41
Source
TipRanks
Investing.com Direct company coverage

Prime Medicine wins arbitration over AATD therapy PM647

Prime Medicine Inc. (NASDAQ:PRME) has won an arbitration against Beam Therapeutics Inc. concerning its investigational therapy PM647 for Alpha-1 Antitrypsin Deficiency, confirming the drug falls within Prime Medicine’s licensed field and no monetary damages are owed. This ruling

Tone
Positive 82/100
Event
Regulatory and legal
Published
08 Jul 2026 12:40
Source
Investing.com
GlobeNewswire Direct company coverage

Prime Medicine Announces Positive Resolution to Arbitration with Beam Therapeutics

Prime Medicine announced a positive resolution to its arbitration with Beam Therapeutics, confirming its right to develop and commercialize PM647 for Alpha-1 Antitrypsin Deficiency (AATD) and owing no monetary damages. The company plans to submit an IND/CTA filing for PM647 in Q3

Tone
Positive 90/100
Event
Market update
Published
08 Jul 2026 11:40
Source
GlobeNewswire
Stock Titan Direct company coverage

Prime Medicine clears Beam dispute, keeps PM647 for AATD

Prime Medicine (Nasdaq: PRME) announced a binding arbitration win against Beam Therapeutics, confirming its right to develop and commercialize PM647 for Alpha-1 Antitrypsin Deficiency (AATD) and owing no damages to Beam. PM647 leverages Prime Editing to correct a prevalent mutati

Tone
Positive 90/100
Event
Market update
Published
08 Jul 2026 11:40
Source
Stock Titan
StocksToTrade Direct company coverage

Prime Medicine Stock Pops As ARK, Analysts Back Gene Editor

Prime Medicine (PRME) stock surged by 15.91% due to significant gene-editing advancements and strong institutional backing. The company received FDA RMAT designation for its PM359 program and clearance from New Zealand for its PM577a trial, marking its first in vivo Prime Editing

Tone
Positive 91/100
Event
Market update
Published
08 Jul 2026 10:03
Source
StocksToTrade